Tag Archives: Taxation

IRC Section 385 Final Regulations

IRC Section 385 Final Regulations

On October 13, 2016, IRS issued final and temporary regulations under 385 addressing the treatment of related party debt.  The final and temporary regulations treat as stock certain related-party interests that otherwise would be treated as indebtedness (the “Request Rule”) for federal tax purposes and established extensive contemptuous documentation requirement (the “Documentation Rule”) with respect to related-party indebtedness.  The Request Rule is effected April 4, 2016 and the Documentation Rule applies to debt instruments issued on or after January 1, 2018.  See our newsletter at http://www.kyjcpa.com/news-updates/proposed-section-385-regulations/ for general overview of the regulations.

The final and temporary regulations retain much of what was previously proposed back in April but reflects certain modifications summarized below:

  • The final and temporary regulations apply to US indebtedness only. Initially, the regulations were drafted to be applied to all related-party debt instruments (both in-bound and out-bound), but the regulations were finalized to excludes foreign debts.
  • The final and temporary regulations eliminated bifurcation rule included in the proposal. Initially, the regulations were drafted to permit the IRS to characterize certain instruments as part debt and part stock, but this bifurcation rule was excluded from the final and temporary regulations.
  • The final and temporary regulations apply to disregarded entities and partnerships having interest in US corporations with related-party debt instruments.
  • The Documentation Rule applies to instruments issued on or after January 1, 2018 and is considered contemporary if completed by the due date of the return (including extension).

Note that the Documentation Rule apply to debt instruments issued by the expanded group with (1) publicly traded stocks, (2) total assets exceeding $100 million, or (3) total revenue exceeding $50 million.  Additionally, a related-party debt instrument will not be treated as stock if, when the debt is issued, the aggregate issue price of all other related-party debt instruments that would be treated as stock does not exceed $50 million.

 

Independent Contractors Vs. Employees

Independent Contractors Vs. Employees

The US Government estimates that approximately 3.5 million employees are classified as independent contractors when they are in fact employees in each year.  This misclassification costs the US Government approximately $55 billion of income taxes and $15 billion of unpaid FICA and unemployment taxes in each year.  For this reason, on-going efforts have been made by the US government to detect misclassification of employees during income tax audits.  Additionally, many state governments have implemented their own examination process to minimize their state tax revenue loss due to the misclassification.

Many employers misclassify employees as independent contractors for a simple reason of saving tax money.  Misclassification can save substantial amount of expenses including employer’s share of Social Security and Medicate taxes, overtime pay, unemployment compensation tax, and workers’ compensation insurance.  However, this practice can cause substantial amount of taxes, penalties and interest, and perhaps criminal charges in some cases, in addition to the potential claims by employees for unpaid compensations (including overtime pay, sick pay, vacation and holiday pay).  Let’s break down the potential tax penalties that employers may face if the misclassification is found to be unintentional:

  • $50 for each reported W-2.
  • 5% failure to withhold income taxes.
  • 40% of employee share of FICA taxes.
  • 100% of employer share of FICA taxes.
  • Up to 25% of failure to pay tax penalties.

IRS looks at degree of control exercised by the employee in determining whether or not a worker is an employee or independent contractor.  Generally, there are three factors, under the Common Law Rules, that should be carefully reviewed in classification.  They are:

  • Behavioral Control – Does the payer control or have the right to control what the worker does and how the worker does his or her job?
  • Financial Control – Are the business aspects of the worker’s job controlled by the payer? These include things like how worker is paid, whether expenses are reimbursed, who provides tools and supplies, etc.
  • Type of Relationship – Are there written contracts or employee type benefits?

If determination of employee or independent contractor based on the above mentioned factors is unclear, payor can submit Form SS-8, Determination of Worker Status for Purposes of Federal Employment Taxes and Income Tax Withholding, and IRS can officially determine the worker’s status.

Also, payors do not have to cover independent contractors under workers’ compensation insurance, and not liable for payments under unemployment insurance, disability insurance, or social security with the state taxing authorities.  Misclassification may expose employers for sever penalty provisions by state government and there are many state agencies (including the Employment Development Department, Division of Labor Standards Enforcement, Franchise Tax Board, Division of Workers’ Compensation, and the Contractors State Licensing Board) with their own regulations or requirements concerning independent contractors enforcing proper classifications.

 

Take Away

Because the potential liabilities and penalties are significant if an individual is treated as an independent contractor and later found to be an employee, each working relationship should be thoroughly researched and analyzed before it is established.

생명과학 및 연구 개발 산업

생명과학 및 연구 개발 산업

생명 과학 산업은 샌디에고 경제의 주요 부문이다. 샌디에고에는1,100 개 이상의 생명 과학 회사와 80 개 이상의 연구 기관이있으며 Pfizer, Johnson & Johnson, GlaxoSmithKline, Merck 등 주요 제약 회사들이 주변 연구 기관, 대학교, 그리고 생명 공학 기업들과 협력하여 거대한 생명과학 산업을 이루고 있다.

이 산업에서 연구 및 개발은 막대한 양의 자본을 필요로 하며, 보통 관련된 회사들은 수익을 창출하기까지 수억달러를 투자해야한다. 연구 시작에 앞서 자금확보는 회사가 가장 처음 직면하는 위험요소이며 가장 중요한 단계일 것이다. 필자는 좋은 아이디어를 가지고 있음에도 불구하고 투자자 확보 및 금융전략에 실패하여 빛을 보지 못하고 파산하는 많은 회사들을 보았다.

현재 회사가 계속되는 적자로 인하여 세금을 내고 있지 않다고 하더라도 세무전략을 세우는것은 매우 중요하다. 세무 전략을 통해 투자자들 뿐만 아니라 금융기관에서 평가하는 투자 가치를 증가 시킬 수 있으며 이것은 미래의 이익을 최대화 할 수 있는 방법이기도 하다. 필자는 이와 관련된 기업 및 회사들이 고려 및 반영해 볼 만한 세무전략을 몇가지 소개 하려고 한다.

 

R & D Credit

지금까지 많은 스타트업 회사들이 순영업손실 (net operating loss)로 인하여 연구개발 세액공제 (R&D Credit)를 신청할 필요성을 느끼지 못했을 것이다. 하지만, 2015년 새로운 세법 (Protecting Americans from Tax Hikes (PATH) Act.)이 제정되면서 조건에 해당하는 small to mid-sized 회사들은 수입이 증가하면서 생기는 법인대체최소세 (Alternative Minimum Tax - AMT)와 고용주가 부담하는 사회보장세 (FICA Tax)에 대한 공제를 받을 수 있게 되었다. 또한, 회사에 소득이 발생하는 시점에 이월하여 사용할 수 있는 크레딧을 적절한 문서화를 통하여 쌓아 갈 수 있다. 이러한 미래형 세금자산 확보는 회사자금의 유동성 확보 및 투자가치상승을 위한 벤처 캐피탈 및 금융기관의 기업평가에 아주 직접적인 영향을 줄 것이다.

Start-up tax losses

세무 상 자본 손실은 이월 기간을 제한하고 있다. 이월 기간 내에 사용되지 않은 모든 손실은 만료기간이 되면 사라지기 때문에 공제 받을 수 있는 타이밍을 관리하고 세무 상 손실의 수명을 연장하기 위해 특정 세금 election 을 이용하는 방법이 중요하다. 또한, 대부분의 회사들은 equity rounds를 이용해 운영 자금을 충당한다. 미국 세입법 (IRC 382)에 따르면 회사 소유권이 변경이 있을 때 마다 세무 상 손실금을 활용하는 금액을 제한한다. 올바른 세금 계획은 이러한 세금 혜택 손실을 최소화하고 법인세 자산 가치를 보존하기 위한 필수 사항이다.

Equity-based compensation

핵심 인재 유지는 많은 초기 단계의 생명 과학 기업이 직면 한 주요 과제 중 하나이다. 많은 기업들이 인재를 유치하기 위해 다양한 형태의 비 현금 보상을 제공한다. 이때 회사가 선택할 수있는 주식 기준 보상 등 여러가지 유형이 있으며, 유형마다 세금 및 재정에 서로 다른 영향을 미친다. 주식 기준 보상을 구현하기 전에 방법의 메커니즘을 알고 장단점을 모두 고려하여 선택해야 할 것이다.

Final Regulations under IRC section 385

최근 미국세청 (IRS)에서 Relate party (특수관계) 사이에서 발생한 채무관계를 정의하는 객관적 기준을 제시하는 규정을 (Regulations under IRC section 385) 발표했다. 해당규정에서는 증빙서류 없이 일어난 회사간의 부채는 소득세 목적으로 “주식”과 같이 취급한다고 명시하고 있다. 즉, 비용처리를 목적으로 사용된 이자비용은 배당금으로 취급한다. 2016년 4월 4일 이후 특수관계 사이에서 발행된 채무증서가 있다면 과세당국과의 충돌을 피하기위해 세금전문가의 도움을 받아 해결할것을 권한다.

International Tax Compliance Issues

소득 이전을 통한 세원 잠식 (Base Erosion and Profit Sharing - BEPS), 매출 축소(Earnings Stripping), 조세 전도(Inversion), 원가분담약정(Cost Share Arrangement) 및 무형자산 이전(Intangible Property Migration)은 근래에 들어 IRS에서 주시하는 주요 항목들이다. IRS는 해당 분야에서 발생하는 문제들에 대하여 추가준수사항 및 엄격한 규정들을 제시하고있다. 이 에 해당하는 세금 문제들은 IRS에 의해 면밀히 조사되며, 불응시 상상할 수 없는 결과를 초래할 수 있다. 다국적 기업은 세금 전문가의 도움을 받아 빠르게 변하고있는 세법을 준수하며 사업 전략 및 세법 전략을 계획하여야 한다.

Click here for English version of this article.

The Protecting Americans from Tax Hikes (PATH) Act

The Protecting Americans from Tax Hikes (PATH) Act

President Obama signed into law The Protecting Americans from Tax Hikes (PATH) Act on December 18, 2015.  The PATH Act includes renewal of number of expired tax deductions, credits, and incentives as summarized below:

  • Research & Experimental Credit – Permanently extended retroactively January 1, 2015.  Certain eligible small business can now use the credit against alternative minimum tax liability and employer portion of their payroll tax liability.
  • Section 179 expense – The Act makes permanent the increased expensing limit to $500,000.
  • Subpart F exception for active financing income – The bill makes permanent the subpart F exception for certain foreign income derived in the active conduct of banking, financing, securities, or insurance business.
  • S-Corporation built-in gains tax recognition Period – The Law permanently reduced the S-corporation built-in gains recognition period from 10 years to 5 years.
  • 100% qualified small business stock gain exclusion – The Act makes qualified small business stock gain provision permanent.
  • Bonus depreciation – The bill extends bonus deprecation from 2015 through 2019:  50% bonus depreciation for assets placed in service in 2015 through 2017, 40% in 2018, and 30% in 2019.
  • Work opportunity tax credit (WOTC) – this hiring related tax credit is extended through 2019.
  • Solar energy investment tax credit – the extender renews investment tax credit for qualified expenditures on solar energy through 2019.
  • State & local sales tax deduction – individuals are allowed to deduct state and local sales taxes in lieu of income taxes permanently.
  • Earned income tax credit & child tax credit – the Act extends for individuals the earned income tax credit and child tax credit through 2017.

Please contact us for further detail of provisions included in the PATH Act.